Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPRNewsWire • 10/21/26
Immunic to present four vidofludimus calcium abstracts at MSToronto2026Proactive Investors • 10/07/26
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPRNewsWire • 10/07/26
Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis TranscriptSeeking Alpha • 09/11/26
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026PRNewsWire • 09/02/26
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/13/26
Immunic advances MS drug toward key Phase 3 data, expects results by year-endProactive Investors • 08/11/26
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 08/11/26
Immunic presents new vidofludimus calcium data at multiple sclerosis conferenceProactive Investors • 05/28/26
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple SclerosisPRNewsWire • 05/28/26
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive OfficerPRNewsWire • 05/27/26
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutProactive Investors • 05/19/26
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of DirectorsPRNewsWire • 05/19/26
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 05/13/26